Quantifying hepatic steatosis - more than meets the eye

Histopathology

Volumn 60, Issue 6, 2012, Pages 971-981

  Levene, Adam P ^a,c   Kudo, Hiromi ^a,c   Armstrong, Matthew J ^a,c   Thursz, Mark R ^b   Gedroyc, Wladyslaw M ^a   Anstee, Quentin M ^a   Goldin, Robert D ^a,c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b University Hospitals Birmingham NHS Foundation Trust   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Digital image analysis; Histopathology; Non alcoholic fatty liver disease; Oil Red O

Indexed keywords

EOSIN; FAT DROPLET; HEMATOXYLIN; LIPID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIGITAL IMAGE ANALYSIS; DIGITAL IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LIPID LIVER LEVEL; LIVER BIOPSY; MALE; MICROSCOPY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

ADIPOSE TISSUE; ANIMALS; AZO COMPOUNDS; BODY WEIGHT; COLORING AGENTS; DISEASE MODELS, ANIMAL; FATTY LIVER; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TRIGLYCERIDES;

EID: 84860283052     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04193.x     Document Type: Article

References (27)

1. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am. J. Gastroenterol. 2007; 102; 399-408.
2. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin. Liver Dis. 2008; 28; 386-395.
3. Mazhar SM, Shiehmorteza M, Sirlin CB. Noninvasive assessment of hepatic steatosis. Clin. Gastroenterol. Hepatol. 2009; 7; 135-140.
4. Sharma P, Martin DR, Pineda N et al. Quantitative analysis of T2-correction in single-voxel magnetic resonance spectroscopy of hepatic lipid fraction. J. Magn. Reson. Imaging 2009; 29; 629-635.
5. Brunt EM. Nonalcoholic steatohepatitis. Semin. Liver Dis. 2004; 24; 3-20.
6. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41; 1313-1321.
7. Abdelmalek MF, Sanderson SO, Angulo P et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009; 50; 1818-1826.
8. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 2006; 87; 1-16.
9. Anstee QM, Concas D, Kudo H et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J. Hepatol. 2010; 53; 542-550.
10. Anstee QM. Animal models in nonalcoholic steatohepatitis research: utility and clinical translation. Liver Int. 2011; 31; 440-442.
11. Bancroft JD, Gamble M. Theory and Practice of Histological Techniques. Edinburgh: Churchill Livingstone, 2007.
12. Zaitoun AM, Al Mardini H, Awad S, Ukabam S, Makadisi S, Record CO. Quantitative assessment of fibrosis and steatosis in liver biopsies from patients with chronic hepatitis C. J. Clin. Pathol. 2001; 54; 461-465.
13. Bley TA, Wieben O, Francois CJ, Brittain JH, Reeder SB. Fat and water magnetic resonance imaging. J. Magn. Reson. Imaging 2010; 31; 4-18.
14. Yamaguchi K, Yang L, McCall S et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45; 1366-1374.
15. Roldan-Valadez E, Favila R, Martinez-Lopez M, Uribe M, Rios C, Mendez-Sanchez N. In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: correlation with biochemical method and morphometry. J. Hepatol. 2010; 53; 732-737.
16. Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J. Hepatol. 1997; 26(Suppl 2); 43-53.
17. Morris AA. Mitochondrial respiratory chain disorders and the liver. Liver 1999; 19; 357-368.
18. Scheuer PJ, Lefkowitch JH. Liver Biopsy Interpretation. Oxford, UK. Saunders, 2006.
19. Selzner N, Selzner M, Jochum W, Amann-Vesti B, Graf R, Clavien PA. Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis. J. Hepatol. 2006; 44; 694-701.
20. Arnault I, Bao YM, Sebagh M et al. Beneficial effect of pentoxifylline on microvesicular steatotic livers submitted to a prolonged cold ischemia. Transplantation 2003; 76; 77-83.
21. Marsman H, Matsushita T, Dierkhising R et al. Assessment of donor liver steatosis: pathologist or automated software? Hum. Pathol. 2004; 35; 430-435.
22. Garcia-Ruiz I, Rodriguez-Juan C, Diaz-Sanjuan T, Martinez MA, Munoz-Yague T, Solis-Herruzo JA. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology 2007; 46; 414-423.
23. Ahmed U, Redgrave TG, Oates PS. Effect of dietary fat to produce non-alcoholic fatty liver in the rat. J. Gastroenterol. Hepatol. 2009; 24; 1463-1471.
24. Bradbury MW. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2006; 290; G194-G198.
25. Ran J, Hirano T, Adachi M. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am. J. Physiol. Endocrinol. Metab. 2004; 287; E227-E232.
26. Reaven GM. Insulin resistance: a chicken that has come to roost. Ann. NY Acad. Sci. 1999; 892; 45-57.
27. De Gottardi A, Vinciguerra M, Sgroi A et al. Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes. Lab. Invest. 2007; 87; 792-806.